1. Volume 12, Issue 11, Pages 1076-1083 (November 2013)
Simvastatin for cognitive deficits and behavioural problems in patients with neurofibromatosis type 1 (NF1-SIMCODA): a randomised, placebo-controlled trial 
Thijs van der Vaart, MSc, Ellen Plasschaert, MSc, André B Rietman, MSc, Marleen Renard, MD, Rianne Oostenbrink, MD, Prof Annick Vogels, MD, Marie-Claire Y de Wit, MD, Mie-Jef Descheemaeker, MSc, Yvonne Vergouwe, PhD, Coriene E Catsman-Berrevoets, MD, Prof Eric Legius, MD, Prof Ype Elgersma, PhD, Prof Henriëtte A Moll, MD 
The Lancet Neurology 
Volume 12, Issue 11, Pages (November 2013)
DOI: /S (13)
Copyright © 2013 Elsevier Ltd Terms and Conditions

2. Figure 1 Trial profile ADHD=attention deficit hyperactivity disorder.
The Lancet Neurology  , DOI: ( /S (13) )
Copyright © 2013 Elsevier Ltd Terms and Conditions

3. Figure 2 Standardised treatment effects
The effect of simvastatin on primary and secondary outcome measures, adjusted for baseline performance, age, and sex. Treatment effects have been converted to SD difference and are accompanied by the corresponding 95% CI. WISC-III-NL=Wechsler intelligence scale for children, third edition, Dutch translation. CBCL=parent-reported child behaviour checklist. CHQ-PF50=child health questionnaire–parent form 50. YSR=youth self-report.
The Lancet Neurology  , DOI: ( /S (13) )
Copyright © 2013 Elsevier Ltd Terms and Conditions